StockNews.com Upgrades Pediatrix Medical Group (NYSE:MD) to "Buy"

Pediatrix Medical Group (NYSE:MD - Get Free Report) was upgraded by investment analysts at StockNews.com from a "hold" rating to a "buy" rating in a research note issued on Wednesday.

Several other research analysts also recently weighed in on MD. Truist Financial dropped their price target on Pediatrix Medical Group from $16.00 to $15.00 and set a "hold" rating for the company in a research note on Monday, January 6th. UBS Group raised their target price on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the company a "hold" rating in a report on Monday, November 4th. Macquarie initiated coverage on Pediatrix Medical Group in a research report on Monday, December 16th. They set an "outperform" rating and a $18.00 price objective for the company. Finally, Jefferies Financial Group lifted their target price on Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a "buy" rating in a report on Tuesday, November 5th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $16.25.

Pediatrix Medical Group Price Performance

Shares of NYSE MD traded up $0.08 during midday trading on Wednesday, reaching $14.08. The stock had a trading volume of 593,603 shares, compared to its average volume of 491,431. The company has a market capitalization of $1.21 billion, a price-to-earnings ratio of -4.60, a price-to-earnings-growth ratio of 1.40 and a beta of 1.58. Pediatrix Medical Group has a 12-month low of $6.62 and a 12-month high of $16.41. The stock has a 50-day moving average of $14.00 and a 200-day moving average of $11.97. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.42 and a current ratio of 1.42.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last issued its quarterly earnings results on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The business had revenue of $511.20 million during the quarter, compared to analyst estimates of $498.87 million. During the same quarter in the prior year, the business posted $0.29 EPS. Pediatrix Medical Group's revenue for the quarter was up .9% compared to the same quarter last year. As a group, research analysts anticipate that Pediatrix Medical Group will post 1.26 EPS for the current fiscal year.

Insiders Place Their Bets

In other Pediatrix Medical Group news, Director Mark S. Ordan sold 27,600 shares of the firm's stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total value of $423,660.00. Following the completion of the sale, the director now owns 138,683 shares of the company's stock, valued at $2,128,784.05. This trade represents a 16.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Mary Ann E. Moore sold 8,108 shares of the company's stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $16.00, for a total value of $129,728.00. Following the transaction, the executive vice president now directly owns 135,810 shares in the company, valued at approximately $2,172,960. This represents a 5.63 % decrease in their position. The disclosure for this sale can be found here. 1.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Pediatrix Medical Group

A number of large investors have recently bought and sold shares of MD. Quest Partners LLC raised its stake in shares of Pediatrix Medical Group by 25.6% during the third quarter. Quest Partners LLC now owns 3,054 shares of the company's stock valued at $35,000 after acquiring an additional 622 shares in the last quarter. Quarry LP raised its position in Pediatrix Medical Group by 54.1% during the 3rd quarter. Quarry LP now owns 4,735 shares of the company's stock valued at $55,000 after purchasing an additional 1,662 shares in the last quarter. CWM LLC lifted its holdings in shares of Pediatrix Medical Group by 134.0% in the 3rd quarter. CWM LLC now owns 6,427 shares of the company's stock worth $74,000 after buying an additional 3,681 shares during the period. Canada Pension Plan Investment Board bought a new position in shares of Pediatrix Medical Group during the 2nd quarter worth $72,000. Finally, FMR LLC increased its stake in shares of Pediatrix Medical Group by 220.6% during the third quarter. FMR LLC now owns 9,841 shares of the company's stock valued at $114,000 after buying an additional 6,771 shares during the period. Hedge funds and other institutional investors own 97.71% of the company's stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.